Literature DB >> 2331577

Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome.

A T Dinh Xuan1, T W Higenbottam, C Clelland, J Pepke-Zaba, G Cremona, J Wallwork.   

Abstract

A comparison has been made between the endothelium-dependent relaxation of pulmonary arteries (PA) obtained at heart-lung transplantation from 4 patients with Eisenmenger's syndrome and secondary pulmonary hypertension, and PA obtained at lobectomy from 4 patients with lung carcinoma, the controls. All vascular rings were studied immediately after lung excision. PA rings from control patients dose-dependently relaxed to cumulative doses of acetylcholine (ACh, 10(-10) to 10(-5) M), achieving a maximal relaxation of 80 +/- 5% (mean +/- s.e. mean) from precontraction with phenylephrine. By contrast, PA rings from Eisenmenger's syndrome patients achieved a maximal relaxation of only 34 +/- 12% (P less than 0.05, unpaired t test), with even paradoxical contraction at high doses of ACh (10(-6) to 10(-5) M). Sodium nitroprusside (10(-4) M) relaxed all PA rings, with and without endothelium (carefully removed before study), obtained from both control and Eisenmenger's syndrome patients. These results provide the first evidence that endothelium-dependent relaxation of PA mediated by endothelium-derived relaxing factors is impaired in Eisenmenger's syndrome patients with secondary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2331577      PMCID: PMC1917494          DOI: 10.1111/j.1476-5381.1990.tb14643.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Pulmonary hypertension with special reference to the vasoconstrictive factor.

Authors:  P WOOD
Journal:  Br Heart J       Date:  1958-10

2.  The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I.

Authors:  P WOOD
Journal:  Br Med J       Date:  1958-09-20

3.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.

Authors:  P L Ludmer; A P Selwyn; T L Shook; R R Wayne; G H Mudge; R W Alexander; P Ganz
Journal:  N Engl J Med       Date:  1986-10-23       Impact factor: 91.245

Review 4.  Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein.

Authors:  L J Ignarro
Journal:  Circ Res       Date:  1989-07       Impact factor: 17.367

5.  Reduced endothelium-dependent relaxation of cystic fibrosis pulmonary arteries.

Authors:  A T Dinh Xuan; T W Higenbottam; J Pepke-Zaba; C Clelland; J Wallwork
Journal:  Eur J Pharmacol       Date:  1989-04-25       Impact factor: 4.432

6.  Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.

Authors:  B A Reitz; J L Wallwork; S A Hunt; J L Pennock; M E Billingham; P E Oyer; E B Stinson; N E Shumway
Journal:  N Engl J Med       Date:  1982-03-11       Impact factor: 91.245

7.  Endothelium-dependent relaxation in isolated human arteries and veins.

Authors:  S Thom; A Hughes; G Martin; P S Sever
Journal:  Clin Sci (Lond)       Date:  1987-11       Impact factor: 6.124

8.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

9.  Endothelium-dependent relaxation of human pulmonary arteries.

Authors:  B Greenberg; K Rhoden; P J Barnes
Journal:  Am J Physiol       Date:  1987-02
  9 in total
  18 in total

Review 1.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

2.  Targeting Pulmonary Endothelial Hemoglobin α Improves Nitric Oxide Signaling and Reverses Pulmonary Artery Endothelial Dysfunction.

Authors:  Roger A Alvarez; Megan P Miller; Scott A Hahn; Joseph C Galley; Eileen Bauer; Timothy Bachman; Jian Hu; John Sembrat; Dmitry Goncharov; Ana L Mora; Mauricio Rojas; Elena Goncharova; Adam C Straub
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

Review 3.  Nitric oxide.

Authors:  A J Farrell; D R Blake
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

4.  Impairment of pulmonary-artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to dysfunction of endothelial cell membrane receptors nor to L-arginine deficiency.

Authors:  A T Dinh-Xuan; J Pepke-Zaba; A Y Butt; G Cremona; T W Higenbottam
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

5.  Effects of cromakalim on the electrical slow wave in the circular muscle of guinea-pig gastric antrum.

Authors:  N Katayama; S M Huang; T Tomita; A F Brading
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

6.  Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Authors:  Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba
Journal:  J Heart Lung Transplant       Date:  2010-03-15       Impact factor: 10.247

Review 7.  Endothelium-derived relaxing factor and the pulmonary circulation.

Authors:  G Cremona; A T Dinh Xuan; T W Higenbottam
Journal:  Lung       Date:  1991       Impact factor: 2.584

8.  Maintenance of functional activity of human pulmonary arteries after cryopreservation.

Authors:  P Ellis; E Müller-Schweinitzer
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

9.  Successful pregnancy and delivery in a woman with a single ventricle and Eisenmenger syndrome.

Authors:  M Boukhris; K Hakim; H M'saad; F Ouarda; R Boussaada
Journal:  J Saudi Heart Assoc       Date:  2013-10

10.  Effects of cromakalim on the contraction and the membrane potential of the circular smooth muscle of guinea-pig stomach.

Authors:  K Ito; T Kanno; K Suzuki; K Masuzawa-Ito; T Takewaki; H Ohashi; M Asano; H Suzuki
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.